Drugs Misuse Regulation 1987 Part 1 Preliminary 1 Short title This regulation may be cited as the Drugs Misuse Regulation 1987. 2 Dictionary The dictionary in schedule 9 defines particular words used in this regulation. Part 2 Syringes and dangerous drugs disposal procedures 3 Prescribed procedures for the disposal of hypodermic syringes and needles For the purposes of section 10(4A) of the Act, the prescribed procedures for the disposal of a hypodermic syringe or needle are— (a) by placing the hypodermic syringe or needle in a rigid wall, puncture resistant container and that container is sealed or securely closed in such a manner that its contents are incapable of causing injury to any person; or (b) by giving the hypodermic syringe or needle to a person who is a medical practitioner, pharmacist or person or a member of a class of persons referred to as authorised in section 10(3) of the Act. 4 Prescribed procedure for disposal of dangerous drugs For the purposes of section 125 of the Act, the prescribed procedure for the disposal of a thing is— (a) in the case where the thing is a trace amount of a dangerous drug contained in a hypodermic syringe or needle, by disposing of the hypodermic syringe or needle in accordance with the procedures prescribed in section 3; or (b) in any other case, at the first reasonable opportunity, by giving— (i) such thing; and (ii) where such thing is contained in a hypodermic syringe or needle, such syringe or needle; to an inspector under the Medicines and Poisons Act 2019. Part 3 Controlled substances 5 Other act that is a relevant transaction— Act , s 43C (b) Any act by which a controlled substance is supplied by a person, in or in connection with the person's business, to anyone else is a relevant transaction for the supply of a controlled substance. Example— A and B are partners in a chain of pharmacies. They make cold tablets to sell in the pharmacies by compounding ephedrine (a controlled substance) with other substances. The partners sell some of the left over ephedrine to a pharmaceutical research company and give the rest away. Both the sale and gift of ephedrine are relevant transactions. Editor's note— Under section 43A of the Act— supply means give, distribute, sell or supply. 6 Documents and proof of identity required for supply of a controlled substance or controlled thing— Act , s 43D (1)(a) (1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (a recipient). (2) The person must, before supplying the substance or thing, obtain from the recipient a document (an end user declaration) showing the following information— (a) the recipient's name and address, and if the recipient purports to obtain the substance or thing for another person, the other person's name and address; (b) details of the official document produced by the recipient under subsection (3) as evidence of the recipient's identity; (c) the date and number of the written order for the supply of the substance or thing; (d) the name and quantity of the substance or thing to be supplied; (e) if a thing is supplied—the serial number or unique identifier of the thing; (f) the date on which the substance or thing is to be supplied; (g) the purpose for which the substance or thing is to be supplied. (3) If the recipient is an individual, the person must, before supplying the substance or thing, require the recipient to produce an official document containing the recipient's photograph (for example, a passport or driver licence) as evidence of the recipient's identity. (4) The person must, immediately the person supplies the substance or thing under the transaction, make an invoice for the supply of the substance or thing showing the following details— (a) the recipient's name and address; (b) the recipient's order number for the supply of the substance or thing; (c) the date the substance or thing was supplied; (d) the name and quantity of the substance or thing supplied. Maximum penalty for subsection (4)—20 penalty units. 6A End user declaration to be given to commissioner of police service— Act , s 43D (1)(d) (1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (the recipient). (2) The person must, as soon as practicable after obtaining from the recipient the end user declaration mentioned in section 6(2), give a copy of the end user declaration to the commissioner of the police service. 7 Details about supply of controlled substance or controlled thing to be recorded in register (1) The following details about a relevant transaction for the supply of a controlled substance or controlled thing must be recorded in the register— (a) the name and address of the recipient and, if the recipient purports to obtain the substance or thing for another person, the other person's name and address; (b) the recipient's order number for the supply of the substance or thing; (c) the invoice number for the supply of the substance or thing; (d) if the recipient is— (i) a company—its Australian Company Number; or (ii) an individual—the type of official document produced under section 6(3) and the following details about the document— (A) who issued it; (B) its serial number or other identifying number or mark; (e) the name and quantity of the substance or thing supplied; (f) the date the substance or thing was supplied; (g) the purpose for which the substance or thing was supplied. (2) The details must be recorded in the register as soon as practicable, but in no case later than 7 days, after the day the person supplied the substance or thing under the transaction. (3) Nothing in this section prevents the keeping of a single register for the Act and another Act if— (a) the keeping of the single register is not contrary to the other Act; and (b) the details recorded under subsection (1) are easily identifiable in the single register. Note— See section 43D(1)(c) of the Act for the requirement to keep the register. 8 Details about loss or theft of controlled substance or controlled thing to be recorded in register The following details of the reporting to a police officer of the loss or theft of a controlled substance or controlled thing must be recorded in the register— (a) the day and place the report was made; (b) the name and registered number of the officer to whom the report was made; (c) the name and quantity of the substance or thing lost or stolen. 9 Keeping of register, invoice and other documents (1) This section applies to the register and other documents mentioned in the Act, section 43D(1) and the invoice required under section 6(4). (2) A person who supplies a controlled substance or controlled thing under a relevant transaction must keep the register, documents or invoice— (a) at the principal or only place in Queensland where the person engages in relevant transactions; and (b) for 2 years from the day the person supplied the substance or thing under the transaction. Part 4 Commercial production of industrial cannabis Division 1 Preliminary 10 Operation of pt 4 and schs 7 and 8 (1) Divisions 3 to 6 state activities stated persons are authorised to perform for the purposes of part 5B of the Act. (2) Schedule 7 states conditions applying to particular persons who perform activities stated in divisions 4, 5 and 6. (3) If a word used in this part, schedule 7 or schedule 8 is not defined in the dictionary but is defined for part 5B of the Act, the word has the same meaning as in that part, unless a contrary intention appears. Note— See section 46 of the Act for definitions for pt 5B of the Act. Division 2 Certified cannabis seed 11 Planting seed— Act , s 46 , def planting seed (1) This section states, for section 46 of the Act, definition planting seed, when cannabis seed is taken to have been harvested from a cannabis plant (a 0.5% THC plant) with a THC concentration, in the plant's leaves and flowering heads, of not more than 0.5%. (2) Cannabis seed originating in the State is taken to have been harvested from a 0.5% THC plant if— (a) both of the following apply— (i) an authorised person, at the request of the licensee or on the authorised person's own initiative, arranges for the THC concentration of a representative sample for the seed to be analysed; (ii) the results of the analysis state the THC concentration of the representative sample is not more than 0.5%; and (b) the seed is labelled with the required particulars. Note— See section 27C for additional labelling requirements. (3) Also, cannabis seed originating in the State is taken to have been harvested from a 0.5% THC plant if— (a) both of the following apply— (i) an authorised person, at the request of the licensee or on the authorised person's own initiative, authorises another person in writing to arrange for the THC concentration of a representative sample for the seed to be analysed in a NATA accredited laboratory; (ii) the results of the analysis state the THC concentration of the representative sample is not more than 0.5%; and (b) the seed is labelled with the required particulars. Note— See section 27C for additional labelling requirements. (4) Cannabis seed originating in another State, or another country, is taken to have been harvested from a 0.5% THC plant if the recipient licensee— (a) takes reasonable steps to confirm that— (i) a representative sample for the seed has undergone an analysis that is substantially equivalent to an analysis mentioned in subsection (3)(a)(i); and (ii) the results of the analysis state the THC concentration of the representative sample is not more than 0.5%; and (b) labels the cannabis seed with the required particulars. Note— See section 27C for additional labelling requirements. (5) In this section— authorised person means— (a) an inspector; or (b) another person authorised by the chief executive for the purpose of this section. representative sample, for cannabis seed, means a representative sample of cannabis leaves and flowering heads taken from the crop from which the seed was harvested. Division 3 Carriers 12 Application of div 3 This division applies to a carrier only if the carrier is engaged or employed by any of the following to transport consigned cannabis— (a) a researcher; (b) a grower; (c) a DPI researcher; (d) an inspector; (e) a seed supplier. 13 Supply (1) The carrier is authorised to transport consigned cannabis and give it to the person to whom it is consigned. (2) The authorisation— (a) is for the time necessary for the carrier to transport the consigned cannabis and give it to the person to whom it is consigned; and (b) has effect only while the carrier is acting in accordance with the terms of the carrier's engagement or employment. 14 Possession (1) The carrier is authorised to possess consigned cannabis for the time necessary for the carrier to transport it to the person to whom it is consigned and give it to the person. (2) The authorisation has effect only while the carrier is acting in accordance with the terms of the carrier's engagement or employment. Division 4 DPI researchers 15 Supply A DPI researcher is authorised— (a) to supply class A or class B research cannabis plants and seed to another DPI researcher or a researcher authorised to possess the cannabis plants and seed; and (b) to supply class A and class B research cannabis seed to a grower for use, under the DPI researcher's supervision, as part of a field trial the DPI researcher is conducting on land owned or leased by the grower; and (c) to supply industrial cannabis seed to any of the following— (i) a grower; (ii) a researcher; (iii) another DPI researcher; (iv) a seed handler; (v) the owner or operator of a facility where processed cannabis is, or is to be, used for manufacturing a manufactured product for sale by wholesale or retail; and (d) to supply class A or class B research cannabis seed or industrial cannabis seed to a person in another State who is authorised under the law of that State to possess cannabis seed that, if grown, will produce plants with a THC concentration in their leaves and flowering heads that the person in the other State may possess; and (e) to supply class A or class B research cannabis plants, industrial cannabis plants or processed cannabis to an analyst; and (f) to supply processed cannabis to the owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail. 16 Production A DPI researcher is authorised to produce, for use in plant breeding programs for developing new commercial strains of industrial cannabis— (a) industrial cannabis plants and seed; and (b) class A and class B research cannabis plants and seed. 17 Possession A DPI researcher is authorised to possess any of the following for a purpose mentioned in section 15 or 16— (a) industrial cannabis plants and seed; (b) class A and class B research cannabis plants and seed; (c) processed cannabis. Division 5 Inspectors 18 Supply An inspector is authorised— (a) to supply industrial cannabis plants, class A or class B research cannabis plants or processed cannabis to an analyst to analyse the THC concentration in any of them; and (b) if the inspector is given industrial cannabis plants or seed or class A or class B research cannabis plants or seed for delivery to a particular person who is lawfully entitled to possess the plants or seed—to supply the plants or seed to the person. 19 Possession An inspector is authorised— (a) to possess industrial cannabis plants, class A or class B research cannabis plants or processed cannabis given to the inspector for delivery to an analyst to analyse the THC concentration in the plants or processed cannabis; and (b) to possess industrial cannabis plants or seed or class A or class B research cannabis plants or seed given to the inspector for delivery to a person lawfully entitled to possess the plants or seed. Division 6 Other persons 20 Manufacturer The owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail is authorised to possess processed cannabis for using it for manufacturing a manufactured product. 21 Analyst (1) An analyst is authorised to possess— (a) standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration; and (b) if an authorised person engages or employs the analyst to analyse a substance to determine its THC concentration—the substance for the purpose of the analysis. (2) In this section— authorised person means any of the following— (a) a researcher; (b) a grower; (c) a DPI researcher; (d) an inspector. substance means a substance that an authorised person reasonably believes to be any of the following— (a) industrial cannabis plants; (b) class A or class B research cannabis plants; (c) processed cannabis. 22 Family members (1) A person who is a member of the immediate family of a licensee is authorised to produce, possess or supply a substance if— (a) the licensee is authorised to produce, possess or supply the substance under the Act; and (b) the person's production, possession or supply of the substance is necessary for, or incidental to the licensee's production, possession or supply of the substance. (2) In this section— substance means any of the following— (a) class A research cannabis plants; (b) class A research cannabis seed; (c) class B research cannabis plants; (d) class B research cannabis seed; (e) industrial cannabis plants; (f) industrial cannabis seed; (g) processed cannabis. 23 Employees of authorised persons (1) An employee of an authorised person is authorised to produce, possess, supply or transport a substance if— (a) under the Act, the authorised person is authorised to produce, possess, supply or transport the substance; and (b) the employee's production, possession, supply or transportation of the substance is necessary for, or incidental to, performing the employee's employment or engagement. (2) In this section— authorised person means any of the following— (a) a licensee; (b) a carrier; (c) a DPI researcher; (d) an inspector; (e) a manufacturer; (f) an analyst. employee includes agent. substance means any of the following— (a) class A research cannabis plant; (b) class A research cannabis seed; (c) class B research cannabis plant; (d) class B research cannabis seed; (e) industrial cannabis plant; (f) industrial cannabis seed; (g) processed cannabis. Division 7 Record requirements 24 Record requirements— Act , s 110E This division prescribes, for section 110E of the Act, record requirements for the holder of a relevant authority. 25 Recording information—researchers and growers (1) A licensee, who is a researcher or a grower, must make a written record of each of the following— (a) the strains or varieties of all cannabis seed in the licensee's possession; (b) the strains or varieties of all cannabis plants the licensee is growing; (c) the source and quantity of all cannabis plants and seed supplied to the licensee; (d) if the licensee is the first licensee to take possession of planting seed after the seed enters the State—a report number, or other identifying information, for the report containing the results mentioned in section 11(4)(a)(ii); (e) when and by whom cannabis plants or seed were delivered to the licensee; (f) if cannabis plants or seed is delivered to the licensee by a carrier—the name of the individual who actually delivered the plants or seed; (g) if the licensee supplies cannabis plants or seed to a carrier for delivery to a person— (i) the name of the individual to whom the plants or seed were given for delivery; and (ii) the name of the person to whom it is intended the plants or seed be supplied by the licensee; (h) when cannabis seed is planted by the licensee; (i) if the licensee supplies cannabis plants or seed to another person (the recipient) who is authorised to possess the cannabis plants or seed— (i) the name of the recipient; and (ii) what the recipient intends to use the cannabis plants or seed for; and (iii) for cannabis plants or seed that is not processed cannabis—particulars of how the cannabis plants or seed was grown, or otherwise obtained, by the licensee; and (iv) the date on which the cannabis plants or seed was supplied to the recipient; and (v) the quantity of cannabis plants or seed supplied to the recipient; (j) if the licensee disposes of or destroys cannabis plants or seed— (i) the date the cannabis plants or seed is disposed of or destroyed; and (ii) the method the licensee used to dispose of or destroy the cannabis plants or seed. (2) The licensee must make the record of the information as soon as practicable, but no later than 7 days, after the information becomes available to the licensee. 26 Recording information—seed handlers (1) A seed handler must make a written record of each of the following— (a) the source and quantity of all industrial cannabis seed supplied to the seed handler; (b) when and by whom industrial cannabis seed was delivered to the seed handler; (c) if industrial cannabis seed is delivered to the seed handler by a carrier—the name of the individual who actually delivered the seed; (d) if the seed handler is the first licensee to take possession of planting seed after the seed enters the State—a report number, or other identifying information, for the report containing the results mentioned in section 11(4)(a)(ii); (e) if the industrial cannabis is denatured by the seed handler—how, when and by whom the industrial cannabis seed was denatured; (f) if the seed handler supplies industrial cannabis seed to a carrier for delivery to a person— (i) the name of the person to whom the seed was given for delivery; and (ii) the name of the person to whom it is intended the seed be supplied by the seed handler; (g) the name of each person to whom the seed handler supplies industrial cannabis seed. (2) The seed handler must make the record of the information as soon as practicable, but no later than 7 days, after the information becomes available to the seed handler. 26D [Repealed] 27 Keeping record of information (1) A holder of a relevant authority must keep the record of the information until the end of the first of the following periods— (a) if the authority ends—3 years after the authority ends; (b) if the holder stops being the holder of the authority—2 years after the holder stops being the holder of the authority. (2) The holder must keep the record in a form that is readily accessible, usable and able to be interpreted. Division 7A Notification requirements 27A Notification requirements—researchers and growers (1) This section prescribes, for section 110F of the Act, notification requirements for a licensee who is a researcher or a grower. (2) The licensee must give an inspector written notice— (a) of the planting of cannabis seed by the licensee; and (b) if cannabis plants planted by the licensee will not be harvested—of the following— (i) the plants will not be harvested; (ii) how the licensee will dispose of or destroy the plants; and (c) in relation to a crop of industrial cannabis or class B research cannabis plants planted by the licensee—that the crop is ready to be tested for THC concentration. (3) The licensee must give a notice under this section to an inspector— (a) for a notice mentioned in subsection (2)(a)—within 14 days of the planting of the seed; or (b) for a notice mentioned in subsection (2)(b)—within 3 months of the planting of the cannabis plants; or (c) for a notice mentioned in subsection (2)(c)—at least 4 weeks before the licensee intends to harvest the crop. Division 8 Other provisions 27B Prescribed information for research plans— Act , s 54 (1) This section prescribes, for section 54(2)(d) of the Act, information that must be included in a research plan relating to an application for a researcher licence. (2) The research plan must— (a) describe the research and associated activities proposed to be carried out under the licence; and (b) describe the location of all places where the research and associated activities will be carried out; and (c) identify any risk of non-compliance with the Act that is associated with the research and associated activities; and (d) describe measures proposed to be implemented to manage all risks mentioned in paragraph (c), including, for example— (i) how the following will be secured— (A) cannabis crops, cannabis seed and equipment associated with the research and associated activities; (B) information and records associated with the research and associated activities; and (ii) what security screening protocols will be put in place for the employees, or other persons, dealing with cannabis crops, cannabis seed and equipment associated with the research and associated activities; and (iii) how the researcher will restrict access, of employees or other persons, to cannabis crops, cannabis seed and equipment associated with the research and associated activities; and (iv) how cannabis crops, cannabis seed and equipment associated with the research and associated activities will be safely and securely stored, handled or transported; and (e) contain any additional information stated in a guideline published by the chief executive under subsection (3). (3) For subsection (2)(e), the chief executive may publish, on the department's website, a guideline stating additional information that the chief executive reasonably considers is relevant for the management of risks associated with research and associated activities carried out under a researcher licence. 27C Labelling method (1) This section applies if a provision of this part, or a condition of a licence, requires— (a) cannabis seed to be labelled so as to indicate particular information; or (b) particular information to otherwise be included on a container, however described, of cannabis seed. (2) The requirement is complied with only if the information is— (a) either— (i) written or stamped on— (A) the outside of the container in a position where the information can be clearly seen on the container; or (B) a label that is fixed to the outside of the container in a position where the label can be clearly seen on the container; or (ii) if, because the seed is being supplied in bulk, subparagraph (i) cannot reasonably be complied with—included in a written notice given to a person to whom the seed is supplied before or when the seed is delivered to the person; and (b) written in English; and (c) written in characters that are at least 1.5mm high; and (d) written in characters that are either— (i) dark print on a light background; or (ii) light print on dark background. (3) A notice under subsection (2)(a)(ii) may be fixed to, or form part of, a delivery docket or invoice given to the person to whom the seed is supplied. 28 Fees The fees payable under the Act are stated in section 28A and schedule 8E. 28A Monitoring fees— Act , s 110G (1) For section 110G(1) of the Act, the monitoring fee for the monitoring of activities performed under a relevant authority is provided for in this section and schedule 8E, item 8. (2) The fee stated in schedule 8E, item 8 may consist of, or include, an amount for part of an hour that is the equivalent of the relevant proportion of the hourly rate, stated in the schedule, worked out using 15-minute periods (wholly or partly completed). (3) In addition to the monitoring fee stated in schedule 8E, item 8, the holder of the relevant authority must pay— (a) the fee worked out under subsection (4) for an inspector monitoring the activities to travel between the inspector's usual place of work and the place where the activities are monitored; and (b) if, for monitoring the activities, an inspector takes a sample of cannabis for analysis to determine the THC concentration of the sample—the reasonable cost of analysing the sample. (4) For subsection (3)(a), the fee must be worked out at the rate stated in schedule 8E, item 8 for the time taken for the travel up to a maximum of 2 hours in a day. 29 Licence conditions— Act , s 64 (1) The conditions in schedule 8 are prescribed for section 64(3) of the Act. (2) Unless otherwise expressly stated, the conditions apply to all licensees. Part 5 Transitional provisions 30 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001 (1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of the Drugs Misuse Amendment Regulation (No. 2) 2001 (the amending regulation), continues to apply in relation to an offence against the Act committed before the commencement of the amending regulation. (2) Proceedings for an offence against the Act committed before the commencement of the amending regulation may be continued or started as if the amending regulation had not been made. 31 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002 (1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of this section, continues to apply in relation to an offence against the Act committed before the commencement of this section. (2) Proceedings for an offence against the Act committed before the commencement of this section may be continued or started as if the Drugs Misuse Amendment Regulation (No. 2) 2002 had not been made. Schedule 1 Dangerous drugs Part 1 Non-steroid drugs Amphetamine Cocaine Heroin Lysergide Methylamphetamine 3,4-Methylenedioxymethamphetamine (MDMA) Paramethoxyamphetamine (PMA) Paramethoxymethamphetamine (PMMA) Phencyclidine Part 2 Steroid drugs Androisoxazole Androstenediol Atamestane Bolandiol Bolasterone Bolazine Boldenone (dehydrotestosterone) Bolenol Bolmantalate Calusterone Chlorandrostenolone 4-Chloromethandienone Chloroxydienone Chloroxymesterone (dehydrochloromethyltestosterone) Clostebol (4-chlorotestosterone) Danazol Dehydroepiandrosterone (DHEA) Dihydrolone Dimethandrostanolone Drostanolone Enestebol Epitiostanol Ethyldienolone Ethylestrenol Fluoxymesterone Formebolone (formyldienolone) Furazabol 4-Hydroxy-19-nortestosterone Hydroxystenozol Mebolazine Mepitiostane Mesabolone Mestanolone (androstalone) Mesterolone Methandienone Methandriol Methenolone Methylclostebol Methyltestosterone Methyltrienolone Metribolone Mibolerone Nandrolone Norandrostenolone Norbolethone Norclostebol Norethandrolone Normethandrone Ovandrotone Oxabolone Oxandrolone Oxymesterone Oxymetholone Prasterone Propetandrol Quinbolone Silandrone Stanolone Stanozolol Stenbolone Testosterone, other than in implant preparations for growth promotion in animals Thiomesterone (tiomesterone) Tibolone Trenbolone (trienbolone, trienolone), other than in implant preparations for use in animals Trestolone Any other anabolic and androgenic steroidal agent Schedule 2 Dangerous drugs Acetorphine 4-Acetoxy-N,N-diethyltryptamine (4-AcO-DET) 4-Acetoxy-N,N-dimethyltryptamine (O-Acetylpsilocin) Acetyl-alpha-methylfentanyl N-Acetyl-4-bromo-2,5-dimethoxyphenethylamine (N-Acetyl 2C-B) Acetyldihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of acetyldihydrocodeine per dosage unit; or (b) in undivided preparations containing 2.5% or less of acetyldihydrocodeine. Acetylmethadol Acetylmorphine N-(1-Adamantyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (FUB AKB48) N-(1-Adamantyl)-1-(5-fluoropentyl)-indazole-3-carboxamide (5-Fluoro AKB48) N-(1-Adamantyl)-1-pentyl-indazole-3-carboxamide (APINACA or AKB48) Adamantyl 1-pentyl-indazole-3-carboxylate (APINAC or AKB57) N-(1-Adamantyl)-1-pentyl-indole-3-carboxamide (SDB-001) Alfentanil Alkoxyamphetamines and bromo-substituted alkoxyamphetamines other than where separately specified Alkoxyphenethylamines and alkyl-substituted alkoxyphenethylamines other than where separately specified Alkylthioamphetamines and substituted alkylthioamphetamines other than where separately specified Allobarbital Allylprodine Alphacetylmethadol Alpha-Ethylaminopentiophenone (alpha-EAPP) Alphaethyltryptamine Alphameprodine Alphamethadol Alpha-Methylfentanyl Alpha-Methylthiofentanyl Alphamethyltryptamine (AMT) Alphaprodine Alpha-Pyrrolidinoheptanophenone (PV8) Alpha-Pyrrolidinohexanophenone (alpha-PHP) Alpha-Pyrrolidinovalerophenone (alpha-PVP) Alphenal Alprazolam 2-Aminoindane N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-indazole-3-carboxamide (PX-2) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-indole-3-carboxamide (PX-1) 4-Amino-3-phenylbutanoic acid (Phenibut) 6-(2-Aminopropyl)benzofuran (6-APB) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB) Aminorex Amobarbital Anileridine Aprobarbital Bambuterol Barbital Barbituric acid and any 5,5 disubstituted derivatives of barbituric acid, whether or not further substituted at position 1 of the ring Benzethidine Benzphetamine (N-Benzyl-N-alpha-dimethylphenethylamine) Benzylmorphine N-Benzylpiperazine (BZP) Betacetylmethadol Beta-Hydroxy-3-methylfentanyl Beta-Hydroxyfentanyl Betameprodine Betamethadol Betaprodine Bezitramide Bromazepam 4-Bromo-2,5-dimethoxyamphetamine (DOB, 4-Bromo-DMA) 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) Bromo-Dragonfly (1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-aminopropane) 2-Bromomethcathinone 3-Bromomethcathinone 4-Bromomethcathinone Brotizolam Bufotenine (5-Hydroxy-N,N-dimethyltryptamine) Buprenorphine Butabarbital Butalbital Butallylonal Butethal Butonitazene Butorphanol 1-Butyl-3-(2-methoxybenzoyl)indole (RCS-4(C4) 2-methoxy isomer) 1-Butyl-3-(1-naphthoyl)indole (JWH-073) Camazepam Cannabinoids other than tetrahydrocannibinols Cannabis N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(cyclohexylmethyl)-indole-3-carboxamide (ADB CHMICA) N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (ADB FUBINACA) N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(5-fluoropentyl)-indole-3-carboxamide (5-Fluoro ADBICA) N-(1-Carbamoyl-2-methylpropyl)-1-(cyclohexylmethyl)-indazole-3-carboxamide (AB CHMINACA) N-(1-Carbamoyl-2-methylpropyl)-1-(cyclohexylmethyl)-indole-3-carboxamide (AB CHMICA) N-(1-Carbamoyl-2-methylpropyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (AB FUBINACA) N-(1-Carbamoyl-2-methylpropyl)-1-(2-fluorobenzyl)-indazole-3-carboxamide (AB FUBINACA 2-fluorobenzyl isomer) N-(1-Carbamoyl-2-methylpropyl)-1-(5-fluoropentyl)-indazole-3-carboxamide (5-Fluoro AB PINACA) N-(1-Carbamoyl-2-methylpropyl)-1-(5-fluoropentyl)-indole-3-carboxamide (5-Fluoro ABICA) N-(1-Carbamoyl-2-methylpropyl)-1-pentyl-indazole-3-carboxamide (AB PINACA) [3-(3-Carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB-597) Carfentanil Catha edulis (Khat) Cathine Cathinone Chlordiazepoxide 4-Chloroamphetamine 4-Chloro-2,5-dimethoxyamphetamine (DOC) 2-Chloromethcathinone 3-Chloromethcathinone 4-Chloromethcathinone 1-(5-Chloropentyl)-3-(1-naphthoyl)indole (5-Chloro JWH-018) Chlorphentermine (4-chloro-alpha,alpha-dimethylphenethylamine) Clenbuterol Clobazam Clonazepam Clonitazene Clorazepate Clotiazepam Cloxazolam Coca leaf Codeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 30mg or less of codeine per dosage unit; or (b) in undivided preparations containing 1% or less of codeine. Codeine-N-Oxide Codoxime N-Cumyl-1-(5-fluoropentyl)-7-azaindole-3-carboxamide (CUMYL-5F-P7AICA) N-Cumyl-1-(5-fluoropentyl)-indazole-3-carboxamide (CUMYL-5F-PINACA) N-Cumyl-1-pentyl-indazole-3-carboxamide (CUMYL-PINACA) 4-Cyano-2-dimethylamino-4,4-diphenylbutane 4-Cyano-1-methyl-4-phenylpiperidine Cyclobarbital Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate (URB-602) 1-Cyclohexyl-4-(1,2-diphenylethyl)-piperazine (MT-45) 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8) 1-(Cyclohexylmethyl)-3-(4-methoxy-1-naphthoyl)indole (CHM-081) Cyclopal Delorazepam Desomorphine Desoxypipradrol (2-DPMP) Dextromoramide Dextropropoxyphene Diampromide Diazepam 3,4-Dichloro-N-2-(dimethylamino)cyclohexyl-N-methylbenzamide (U-47700) Diethylpropion Diethylthiambutene N,N-Diethyltryptamine Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or (b) in undivided preparations containing 2.5% or less of dihydrocodeine. Dihydroetorphine Dihydromorphine Dimenoxadol Dimepheptanol Dimethocaine 2,5-Dimethoxyamphetamine (2,5-DMA) 2,5-Dimethoxy-4-ethylamphetamine (DOET) 2,5-Dimethoxy-4-ethylphenethylamine (2C-E) 2,5-Dimethoxy-4-ethylthiophenethylamine (2C-T-2) 2,5-Dimethoxy-4-iodoamphetamine (DOI) 2,5-Dimethoxy-4-methylamphetamine (DOM) 2,5-Dimethoxy-4-propylphenethylamine (2C-P) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) Dimethylamino-1,2-diphenylethane 2-Dimethylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (Dibutylone) N,N-Dimethylamphetamine 1,3-Dimethylamylamine (DMAA or methylhexanamine) 3-(1,2-Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6-H-dibenzo(b,d)pyran 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210) N,N-Dimethyl-3,4-methylenedioxyamphetamine (MDDM) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP 47, 497 C8 homologue) Dimethylthiambutene N,N-Dimethyltryptamine Dioxaphetyl butyrate Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit Dipipanone Drotebanol Ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine Ephedra spp. Ephedrine Erythropoietin (EPO) Erythroxylum coca Erythroxylum nova-granatense Estazolam Ethchlorvynol Ethinamate 4-Ethoxyamphetamine 4-Ethoxy-2,5-dimethoxyamphetamine (MEM) N-Ethylamphetamine Ethylcathinone (2-ethylamino-1-phenyl-propan-1-one) Ethyl Loflazepate Ethylmethylthiambutene Ethylmorphine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of ethylmorphine per dosage unit; or (b) in undivided preparations containing 2.5% or less of ethylmorphine. N-Ethyl-1-phencyclohexylamine Ethylphenidate Ethyl 1-(phenylacetyl)-L-prolylglycinate (GVS-111) Etizolam Etodesnitazene (Etazene) Etonitazene Etonitazepipne Etonitazepyne Etorphine Etoxeridine Etryptamine Fencamfamin Fenethylline (Theophylline-ethylamphetamine) Fenoterol Fenproporex (N-2-Cyanoethylamphetamine) Fentanyl Flubromazepam Flubromazolam Fludiazepam Flunitazene Flunitrazepam 2-Fluoroamphetamine 3-Fluoroamphetamine 4-Fluoroamphetamine (1-(4-Fluorobenzyl)-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144) 2-Fluoromethamphetamine 3-Fluoromethamphetamine 4-Fluoromethamphetamine 2-Fluoromethcathinone 3-Fluoromethcathinone 4-Fluoromethcathinone 1-(5-Fluoropentyl)-3-(1-adamantylamido)indole (STS-135) (1-(5-Fluoropentyl)-1-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA) 1-(5-Fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole (EAM-2201) 1-(5-Fluoropentyl)-3-(4-fluoro-1-naphthoyl)indole (FAM-2201) (1-(5-Fluoropentyl)-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone (XLR-11; 5-Fluoro UR-144) 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694) 1-(5-Fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (5-Fluoro JWH-122) 1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole (THJ-2201) 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM-2201) 1-(5-Fluoropentyl)-N-(phenylmethyl)-1-indole-3-carboxamide (5-Fluoro SDB-006) 1-(p-Fluoro)phenylpiperazine Flurazepam Formoterol other than in metered aerosols for inhalation Furethidine Gamma hydroxybutyric acid (GHB) Glutethimide Growth Hormone (hGH) Halazepam Haloxazolam Harmaline Harmalol Heptabarbital Hexethal Hexobarbital 1-Hexyl-3-(1-naphthoyl)indole (JWH-019) Hydrocodone Hydromorphinol Hydromorphone 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP 47,497) 4-Hydroxy-N,N-diethyltryptamine (4-HO-DET) N-(2-Hydroxyethyl)-alpha-methylbenzeneethanamine N-Hydroxy-3,4-methylenedioxyamphetamine (N-Hydroxy-MDA) 4-Hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET) 4-Hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MIPT) Hydroxypethidine 5-Hydroxy tryptophan (5-HTP) other than in preparations containing 100mg or less of 5-HTP per dosage unit Insulin-like Growth Factor-1 (IGF-1) 4-Iodo-2,5-dimethoxyphenethylamine (2C-I) Isomethadone Isotonitazene Ketamine Ketazolam Ketobemidone Lefetamine (N,N-Dimethyl-alpha-phenylphenethylamine) Levomethorphan Levophenacylmorphan Levorphanol Lophophora (peyote) Loprazolam Lorazepam Lormetazepam Levomoramide Lysergamide and N-alkyl derivatives of lysergamide other than lysergide Lysergic acid Mazindol Mecloqualone (3-(2-Chlorophenyl)-2-methyl-4(3H)-quinazolinone) Medazepam Mefenorex (N-(3-Chloropropyl)-alpha-methylphenethylamine) Mephobarbital Meprobamate Mescaline (3,4,5-Trimethoxyphenethylamine) Mesocarb (3-(Alpha-methylphenethyl)-N-(phenylcarbamoyl)sydnone imine) Metazocine Methabarbital Methadone Methaqualone (2-Methyl-3-(2-methylphenyl)-4(3H)-quinazolinone) Methcathinone Methiopropamine Methoxetamine 5-Methoxy alphamethyltryptamine (5-MeO-AMT) 4'-Methoxy-alpha-pyrrolidinopropiophenone (MOPPP) N-(2-Methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine (25B-NBOMe) N-(2-Methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) N-(2-Methoxybenzyl)-2,5-dimethoxy-3,4-dimethylphenethylamine (25G-NBOMe) N-(2-Methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOMe) 5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT) 5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) 5-Methoxy dimethyltryptamine 4-Methoxymethcathinone (Methedrone) 5-Methoxy-N-methyl-N-allyltryptamine (5-MeO-MALT) 5-Methoxy-3,4-methylenedioxyamphetamine (MMDA) 5-Methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MIPT) 4-Methoxyphenyl-(1-butyl-1H-indol-3-yl)-methanone (RCS-4 (C4)) 2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone (JWH-201) 2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250) 2-(3-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-302) Methyl (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-Acetoxy-6a,10b-dimethyl-4,10-dioxo-dodecahydro-2-(3-furyl)-2H-naphtho{2,1-c]pyran-7-caboxylate (Salvinorin A) 4'-Methyl-alpha-pyrrolidinohexanophenone (MPHP) 4'-Methyl-alpha-pyrrolidinopropiophenone (MePPP) N-Methyl-2-aminoindane 2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB) 2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (Butylone) 2-Methylamino-1-phenyl-1-butan-1-one (Buphedrone) 2-(Methylamino)-1-phenylpentan-1-one (Pentedrone) 2-Methylamino-1-phenyl-1-propanone 2-(2-Methylaminopropyl)benzofuran (2-MAPB) 5-(2-Methylaminopropyl)benzofuran (5-MAPB) 6-(2-Methylaminopropyl)benzofuran (6-MAPB) 4-Methylaminorex 4-Methyl-N-benzylcathinone (Benzedrone) Methyl 2-(1-(cyclohexylmethyl)-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB CHMICA) Methyl 2-(1-(cyclohexylmethyl)-indole-3-carboxamido)-3-methylbutanoate (MMB CHMICA) Methyldesorphine Methyldihydromorphine 3',4'-Methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP) 3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP) 5,6-Methylenedioxy-2-aminoindane (MDAI) 3,4-Methylenedioxyamphetamine (MDA) 3',4'-Methylenedioxy-N-benzylcathinone (BMDP) 1-(3,4-Methylenedioxy)-N,N-dimethylcathinone (Dimethylone) 3,4-Methylenedioxyethylamphetamine (MDEA) 1-(3,4-Methylenedioxy)ethylcathinone (Ethylone) 1-(3,4-Methylenedioxy)methcathinone (methylone) 3,4-Methylenedioxypyrovalerone (MDPV) 4-Methylethylcathinone (4-MEC) 3-Methylfentanyl Methyl 2-(1-(4-fluorobenzyl)-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB FUBINACA) Methyl 2-(1-(4-fluorobenzyl)-indazole-3-carboxamido)-3-methylbutanoate (AMB FUBINACA) Methyl 2-(1-(5-fluoropentyl)-indazole-3-carboxamido)-3-methylbutanoate (5-Fluoro AMB) Methyl 2-(1-(5-fluoropentyl)-indole-3-carboxamido)-3-methylbutanoate (MMB-2201) 4-Methylmethcathinone 4-Methylmethylamphetamine (4-MMA) 2-Methyl-3-morpholino-1, 1-diphenylpropane carboxylic acid Methylphenidate Methylphenobarbital 1-[1-(4-Methylphenyl)cyclohexyl]piperidine 1-Methyl-4-phenylpiperidine-4-carboxylic acid 1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-adamantoyl)indole (AM-1248) 1-[(N-Methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole (AM-2233) 1-[(N-Methylpiperidin-2-yl)methyl]-3-(4-methyl-1-naphthoyl)indole (MAM-1220) 1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole (AM-1220) N-Methyl-3-piperidyl benzilate 4-Methylthioamphetamine (4-MTA) 3-Methylthiofentanyl Methyprylon Metodesnitazene Metonitazene Metopon Midazolam Mitragyne speciosa (kratom) Moramide Morpheridine Morphine Morphine methobromide Morphine-N-oxide 1-[(2-(4-Morpholinyl)ethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (A-796260) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) Myrophine Nabilone Nalbuphine Nalorphine Naphthalen-1-yl 1-(4-fluorobenzyl)-indole-3-carboxylate (FDU-PB-22) Naphthalen-1-yl 1-(5-fluoropentyl)-indole-3-carboxylate (NM-2201) Naphthalen-1-yl 1-pentyl-indazole-3-carboxylate (SDB-005) N-(1-Naphthalenyl)-1-pentyl-indole-3-carboxamide (NNEI) Naphthoyl indole Naphthylpyrovalerone (Naphyrone) Nicocodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of nicocodine per dosage unit; or (b) in undivided preparations containing 2.5% or less of nicocodine. Nicodicodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of nicodicodine per dosage unit; or (b) in undivided preparations containing 2.5% or less of nicodicodine. Nicomorphine Nimetazepam Nitrazepam Noracymethadol 6-Nor-6-allyl-lysergic acid diethylamide (AL-LAD) Norcodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of norcodeine per dosage unit; or (b) in undivided preparations containing 2.5% or less of norcodeine. Nordazepam Norlevorphanol Normethadone Normorphine Norpipanone Opium Oxazepam Oxazolam Oxycodone Oxymorphone Papaver bracteatum Papaver orientale Papaver somniferum other than the seed thereof which seed has been rendered sterile Para-Fluorofentanyl Parahexyl Pemoline Pentazocine Pentobarbital 1-Pentyl-3-(1-adamantoyl)indole (AB-001) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210) (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4) 1-Pentyl-3-(2-methoxybenzoyl)indole (RCS-4 (2-methoxy isomer)) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018) Pethidine Phenadoxone Phenampromide Phenazepam Phenazocine Phendimetrazine Phenmetrazine Phenobarbital Phenomorphan Phenoperidine Phentermine (alpha,alpha-Dimethylphenethylamine) 1-(1-Phenylcyclohexyl)pyrrolidine (PCPy) Phenylmethylbarbituric Acid 1-[1-(Phenylmethyl)cyclohexyl]piperidine 4-Phenylpiperidine-4-carboxylic acid ethyl ester Phenylpiracetam 1-Phenyl-N-propylcyclohexanamine Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or (b) in undivided preparations containing 2.5% or less of pholcodine. Phthalimidopropiophenone Piminodine Pinazepam Pipradol Piritramide Pravadoline (WIN 48098) Prazepam Probarbital Proheptazine Propallylonal Properidine Propiram Propylhexedrine (1-cyclohexyl-2-methylaminopropane) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015) N-Propyl-3,4-methylenedioxyamphetamine (MDPR) Protonitazene Psilocin (4-Hydroxy-N,N-dimethyltryptamine) Psilocybin (O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine) Pyrovalerone N-Pyrrolidino protonitazene (Protonitazepyne) Quazepam Quinolin-8-yl 1-(cyclohexylmethyl)-indole-3-carboxylate (BB-22) Quinolin-8-yl 1-(4-fluorobenzyl)-indole-3-carboxylate (FUB-PB-22) Quinolin-8-yl 1-(5-fluoropentyl)-indazole-3-carboxylate (5-Fluoro NPB-22) Quinolin-8-yl 1-(5-fluoropentyl)-1-indole-3-carboxamide Quinolin-8-yl 1-(5-fluoropentyl)-indole-3-carboxylate (5-Fluoro PB-22) Quinolin-8-yl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) Quinolin-8-yl 1-pentyl-1-indazole-3-carboxamide (THJ) Quinolin-8-yl 1-pentyl-indazole-3-carboxylate (NPB-22) Quinolin-8-yl 1-pentyl-indole-3-carboxylate (PB-22) Racemethorphan Racemoramide Racemorphan Remifentanil Reproterol Salbutamol other than in metered aerosols or dry powder or capsules of dry powder for inhalation Salvia divinorum Secobarbital Sigmodal Somatotropin Sufentanil Talbutal Temazepam Terbutaline, other than in metered aerosols for inhalation Testolactone Tetrahydrocannabinols including their alkyl homologues other than where separately specified; and their corresponding carboxylic acids 2,2,3,3-Tetramethyl-N'-(2-oxo-(1-(5-fluoropentyl)indolin-3-yliden))-cyclopropanecarbohydrazide Tetrazepam Thebacon Thebaine Thialbarbital Thiamylal 1-(1-(2-Thienyl)cyclohexyl)piperidine (TCP) Thiobarbituric Acid Thiofentanyl Thiopental Tilidine Triazolam 1-(3-Trifluoromethylphenyl) piperazine (TFMPP) Trimeperidine 2,4,5-Trimethoxyamphetamine 3,4,5-Trimethoxyamphetamine Vinbarbital Vinylbital Zeranol Zipeprol (1-(2-Methoxy-2-phenylethyl))-4-(2-hydroxy-3-methoxy-3- phenylpropyl) piperazine Zolazapam Zolpidem Schedule 3 Specified quantities for particular dangerous drugs Part 1 Quantities of non-steroid drugs Dangerous drug Quantity of dangerous drug Amphetamine 2.0g Barbituric Acid and any 5,5 disubstituted derivatives of barbituric acid whether or not further substituted at position 1 of the ring 50.0g 4-Bromo-2,5-dimethoxyamphetamine 0.5g 4-Bromo-2,5-dimethoxyphenethylamine 2.0g Cannabis 500.0g or, if the dangerous drug consists of plants the aggregate weight of which is less than 500.0g, 100 plants Cocaine 2.0g Codeine 10.0g N,N-Diethyltryptamine 2.0g 2,5-Dimethoxy-4-Ethylamphetamine (DOET) 2.0g 2,5-Dimethoxy-4-Methylamphetamine 2.0g N,N-Dimethyltryptamine 2.0g Fenethylline 2.0g Fentanyl 0.01g Gamma hydroxybutyric acid 2.0g Heroin 2.0g Hydromorphone 2.0g Lysergide 0.004g Methadone 2.0g Methcathinone 2.0g 5-Methoxy-3,4-Methylenedioxyamphetamine (MMDA) 2.0g 2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB) 2.0g 4-Methylaminorex 2.0g Methylamphetamine 2.0g 3,4-Methylenedioxyamphetamine (MDA) 2.0g 3,4-Methylenedioxyethylamphetamine (MDEA) 2.0g 3,4-Methylenedioxymethamphetamine (MDMA) 2.0g 4-Methylthioamphetamine (4-MTA) 2.0g Moramide 2.0g Morphine 2.0g Opium 20.0g Paramethoxyamphetamine (PMA) 2.0g Paramethoxymethamphetamine (PMMA) 2.0g Pethidine 10.0g Phencyclidine 0.5g Psilocin 0.10g Psilocybin 0.10g Tetrahydrocannabinols including their alkyl homologues except where separately specified; and their corresponding carboxylic acids 2.0g 3,4,5-Trimethoxyamphetamine (TMA) 2.0g Part 2 Quantities of steroid drugs Dangerous drug Whole weight of dangerous drug a dangerous drug mentioned in schedule 1, part 2 50.0g Schedule 4 Specified quantities for particular dangerous drugs Part 1 Quantities of non-steroid drugs Dangerous drug Quantity of dangerous drug Amphetamine 200.0g Cocaine 200.0g Heroin 200.0g Lysergide 0.4g Methylamphetamine 200.0g 3,4-Methylenedioxymethamphetamine (MDMA) 200.0g Paramethoxyamphetamine (PMA) 200.0g Paramethoxymethamphetamine (PMMA) 200.0g Phencyclidine 50.0g Part 2 Quantities of steroid drugs Dangerous drug Whole weight of dangerous drug a dangerous drug mentioned in schedule 1, part 2 5,000.0g Schedule 5 Dangerous drugs Alprazolam Bromazepam Brotizolam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Delorazepam Diazepam Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or (b) in undivided preparations containing 2.5% or less of dihydrocodeine. Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit Estazolam Ethyl Loflazepate Fludiazepam Flurazepam Halazepam Haloxazolam Ketazolam Loprazolam Lorazepam Lormetazepam Medazepam Midazolam Nimetazepam Nitrazepam Nordazepam Oxazepam Oxazolam Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained— (a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or (b) in undivided preparations containing 2.5% or less of pholcodine. Pinazepam Prazepam Quazepam Temazepam Tetrazepam Triazolam Zolazapam Schedule 6 Controlled substances Substance Alternative name Acetaldehyde Acetic anhydride N-Acetylanthranilic acid 2-Acetamidobenzoic acid Allylbenzene 3-Phenyl-1-propene or 2-propenyl benzene 4-Allylpyrocatechol Alpha-methyl-3,4- methylenedioxyphenylpropanaldoxime Alpha-methyl-3,4- methylenedioxyphenylpropanamide Alpha-methylstyrene Alpha-phenylacetoacetonitrile (APAAN) Ammonium formate Anethole 4-Anilino-N-phenethylpiperidine (ANPP) Anthranilic acid 2-Aminobenzoic acid Benzaldehyde 1,3-Benzodioxole Benzyl bromide α-Bromotoluene Benzyl chloride α-Chlorotoluene Benzyl cyanide Boron tribromide Bromobenzene Phenylbromide 5-Bromo-1,3-benzodioxole 3,4-Methylenedioxybromobenzene Bromo safrole 1,4-Butanediol Tetramethylene glycol Calcium metal 1-Chlorophenyl-2-aminopropane Chromic acid Chromium trioxide Chromium (VI) oxide Ephedrine Ergometrine Ergonovine Ergotamine Ethanamine Monoethylamine N-Ethylephedrine Ethyl phenylacetate Benzeneacetic acid, ethyl ester N-Ethylpseudoephedrine Eugenol Formaldehyde Formamide Gamma-Aminobutyric acid (GABA) 4-Aminobutanoic acid Helional Hydriodic acid Hydrogen iodide solution Hydrobromic acid Hydrogen bromide solution 4-Hydroxybutanal 4-Hydroxybutyraldehyde 4-Hydroxybutanoic acid lactone Gamma-butyrolactone 4-Hydroxybutanoic acid nitrile 4-Hydroxybutyronitrile 4-Hydroxypentanoic acid Gamma-Hydroxyvaleric acid 4-Hydroxypentanoic acid lactone Gamma-valerolactone 2-Hydroxytetrahydrofuran Tetrahydro-2-furanol Hypophosphorous acid Phosphinic acid Iodine Isosafrole 5-(1-Propenyl)-1,3-benzodioxole Lithium aluminium hydride Lithium metal Magnesium metal Mandelic acid Alpha-Hydroxyphenylacetic acid Mercuric chloride Mercury bichloride or Mercury (II) chloride Mercury metal Methylamine Aminomethane or Monomethylamine Methylammonium salts 3,4-Methylenedioxphenylacetic acid 3,4-Methylenedioxyphenyl-2-propanone N-Methylephedrine N-Methylformamide Methyl phenylacetate Benzeneacetic acid, methyl ester N-Methylpseudoephedrine Nitroethane Nitromethane Norpseudoephedrine Palladium Paramethoxyphenyl-2-propanone N-(2-Phenethyl)-4-piperidinone (NPP) Phenylacetamide Phenylacetic acid Phenylacetonitrile Benzeneacetonitrile, Benzyl cyanide or Benzyl nitrile Phenylacetyl chloride 1-Phenyl-2-bromopropane 1-Phenyl-2-chloropropane 1-Phenyl-2-iodopropane 1-Phenyl-2-methylaminopropane 1-Phenyl-2-nitropropene 1-Phenyl-2-propanol Phenylpropanolamine Norephedrine 1-Phenyl-1-propanone Phenyl ethyl ketone or Propiophenone 1-Phenyl-2-propanone Benzyl methyl ketone or Phenylacetone 1-Phenyl-2-propanone oxime Phosphorous acid Phosphonic Acid Phosphorus (red or white) Piperidine Piperonal Heliotropine or 3,4-Methylenedioxybenzaldehyde Platinum metal Potassium metal Propionic anhydride Pseudoephedrine Pyridine 2-Pyrrolidone Gamma-butyrolactam Raney nickel Safrole 5-(2-Propenyl)-1,3-benzodioxide Sassafras oil Sodium bis(2-methoxyethoxy) aluminium hydride Sodium borohydride Sodium cyanoborohydride Sodium metal Thionyl chloride Thorium Trans-beta-methylstyrene Schedule 7 Conditions for particular persons authorised under part 4 1 DPI researcher A DPI researcher must— (a) keep class A research cannabis plants the researcher is growing securely locked in a glasshouse; and (b) grow class B research cannabis plants in an area that is fenced to delineate the area under production; and (c) if the chief executive requires the researcher to erect signs indicating the presence of class B research cannabis at a fenced area, ensure the signs are erected as required by the chief executive; and (d) keep industrial cannabis seed and class A and class B research cannabis seed in the researcher's possession or under the researcher's control locked in a secure place when not otherwise required— (i) for use for planting; or (ii) to be supplied to another person; and (e) keep a register that includes the following information— (i) the varieties or strains of cannabis plants and cannabis seed under the researcher's control; (ii) the source, quantity and delivery details for cannabis seed and plant varieties the researcher receives; (iii) how, when and from whom the researcher received cannabis plants and seed delivered to the researcher; (iv) if a carrier delivered the cannabis plants or seed to the researcher, the name of the person who delivered the plants or seed; (v) if a researcher engages a carrier to deliver cannabis plants or seed to someone else— (A) the name of the person to whom the plants or seed were given for delivery; and (B) the name of the person to whom it is intended the plants or seed be supplied by the researcher. 2 Inspector An inspector who possesses industrial cannabis plants or seed or class A or class B research cannabis plants or seed for supplying them to someone else under part 4 must keep the plants or seed in a secure place until the inspector supplies them to the person. 3 Analyst (1) This section applies if an analyst is engaged or employed to analyse a substance to determine its THC concentration. (2) The analyst must analyse the substance in a NATA accredited laboratory. (3) The analyst must keep standard THC material in a securely locked place other than when the analyst is using the material in analysing the substance to determine its THC concentration. (4) The analyst must keep the substance in a securely locked place other than when the analyst is analysing the substance. (5) In this section— substance means a substance the analyst reasonably believes to be any of the following— (a) industrial cannabis plants; (b) class A or class B research cannabis plants; (c) processed cannabis. 4 [Repealed] Schedule 8 Licence conditions Part 1 General conditions 1 A licensee must keep cannabis seed in the licensee's possession in a securely locked place, other than when the licensee uses the seed for a purpose that is authorised under the licensee's licence. 2 As soon as reasonably practicable after a licensee receives a package containing cannabis plants or seed that appears to have been tampered with, the licensee must inform an inspector or a police officer that the package appears to have been tampered with. 3 A licensee who proposes to supply industrial cannabis seed for sale by wholesale or retail must ensure— (a) if the seed is cannabis seed harvested from an industrial cannabis plant—the seed is labelled so as to describe the seed as cannabis seed harvested from an industrial cannabis plant; or (b) if the seed is to be supplied as planting seed—the seed is labelled with the required particulars. Note— See section 27C for additional labelling requirements. Part 2 Particular conditions for researcher licences 4 A researcher, whose licence is subject to a condition prohibiting the researcher from dealing with class A research cannabis plants and seed, must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the researcher that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a concentration of THC in their leaves and flowering heads of 3% or more. 5 A researcher, whose licence is subject to a condition prohibiting the researcher from dealing with class A research cannabis plants and seed, must ensure, as far as practicable, that cannabis seed supplied to the researcher by a person in another State or a foreign country is certified as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of less than 3%. 6 A researcher must carry out activities under the researcher's licence in accordance with the approved research plan for the licence. Part 3 Particular conditions for grower licences 7 A grower must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the grower that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a THC concentration in their leaves and flowering heads of more than 1%. Part 4 Particular conditions for seed handler licences 8 A seed handler must— (a) ensure all industrial cannabis seed in the possession of the seed handler is labelled to state— (i) if the seed is cannabis seed harvested from an industrial cannabis plant—that fact; or (ii) if the seed is intended to be used or supplied as planting seed—the required particulars; and Note— See section 27C for additional labelling requirements. (b) pack all industrial cannabis seed to be delivered to someone else by a carrier in a way that ensures, as far as reasonably practicable, seed can not escape from the packaging or be accidentally released or tampered with. Schedule 8A Gross weight of relevant substances for ss 9A, 9B, 9C and 9D of Act Part 1 Substances that include their salts, derivatives and stereo-isomers 1 In this part, a reference to a substance includes a reference to— (a) a salt, derivative or stereo-isomer of the substance; and (b) a salt of a derivative or stereo-isomer of the substance. Substance Alternative name Gross weight Acetaldehyde 0.1g N-Acetylanthranilic acid 2-Acetamidobenzoic acid 0.1g Allylbenzene 3-Phenyl-1-propene or 2-propenyl benzene 0.1g 4-Allylpyrocatechol 0.1g Alpha-methyl-3,4- methylenedioxyphenylpropanaldoxime 0.1g Alpha-methyl-3,4- methylenedioxyphenylpropanamide 0.1g Alpha-methylstyrene 0.1g Alpha-phenylacetoacetonitrile (APAAN) 0.1g Ammonium formate 0.1g Anethole 0.1g 4-Anilino-N-phenethylpiperidine (ANPP) 0.1g Anthranilic acid 2-Aminobenzoic acid 0.1g Benzaldehyde 0.1g 1,3-Benzodioxole 0.1g Benzyl bromide α-Bromotoluene 0.1g Benzyl chloride α-Chlorotoluene 0.1g Benzyl cyanide 0.1g Boron tribromide 0.1g Bromobenzene Phenylbromide 0.1g 5-Bromo-1,3-benzodioxole 3,4-Methylenedioxybromobenzene 0.1g Bromo safrole 0.1g 1,4-Butanediol Tetramethylene glycol 0.1g 1-Chlorophenyl-2-aminopropane 0.1g Chromic acid 0.1g Chromium trioxide Chromium (VI) oxide 0.1g Ephedrine 0.1g Ergometrine Ergonovine 0.1g Ergotamine 0.1g Ethanamine Monoethylamine 0.1g N-Ethylephedrine 0.1g Ethyl phenylacetate Benzeneacetic acid, ethyl ester 0.1g N-Ethylpseudoephedrine 0.1g Eugenol 0.1g Formaldehyde 0.1g Formamide 0.1g Gamma-Aminobutyric acid (GABA) 4-Aminobutanoic acid 0.1g Helional 0.1g 4-Hydroxybutanal 4-Hydroxybutyraldehyde 0.1g 4-Hydroxybutanoic acid lactone Gamma-butyrolactone 0.1g 4-Hydroxybutanoic acid nitrile 4-Hydroxybutyronitrile 0.1g 4-Hydroxypentanoic acid Gamma-Hydroxyvaleric acid 0.1g 4-Hydroxypentanoic acid lactone Gamma-valerolactone 0.1g 2-Hydroxytetrahydrofuran Tetrahydro-2-furanol 0.1g Hypophosphorous acid Phosphinic acid 0.1g Isosafrole 5-(1-Propenyl)-1,3-benzodioxole 0.1g Lithium aluminium hydride 0.1g Mandelic acid Alpha-Hydroxyphenylacetic acid 0.1g Mercuric chloride Mercury bichloride or Mercury (II) chloride 0.1g Methylamine Aminomethane or Monomethylamine 0.1g Methylammonium salts 0.1g 3,4-Methylenedioxphenylacetic acid 0.1g 3,4-Methylenedioxyphenyl- 2-propanone 0.1g N-Methylephedrine 0.1g N-Methylformamide 0.1g Methyl phenylacetate Benzeneacetic acid, methyl ester 0.1g N-Methylpseudoephedrine 0.1g Nitroethane 0.1g Nitromethane 0.1g Norpseudoephedrine 0.1g Palladium 0.1g Paramethoxyphenyl-2-propanone 0.1g N-(2-Phenethyl)-4-piperidinone (NPP) 0.1g Phenylacetamide 0.1g Phenylacetic acid 0.1g Phenylacetonitrile Benzeneacetonitrile, Benzyl cyanide or Benzyl nitrile 0.1g Phenylacetyl chloride 0.1g 1-Phenyl-2-bromopropane 0.1g 1-Phenyl-2-chloropropane 0.1g 1-Phenyl-2-iodopropane 0.1g 1-Phenyl-2-methylaminopropane 0.1g 1-Phenyl-2-nitropropene 0.1g 1-Phenyl-2-propanol 0.1g Phenylpropanolamine Norephedrine 0.1g 1-Phenyl-1-propanone Phenyl ethyl ketone or Propiophenone 0.1g 1-Phenyl-2-propanone Benzyl methyl ketone or Phenylacetone 0.1g 1-Phenyl-2-propanone oxime 0.1g Piperidine 0.1g Piperonal Heliotropine or 3,4-Methylenedioxybenzaldehyde 0.1g Propionic anhydride 0.1g Pseudoephedrine 50g or 1L Pyridine 0.1g 2-Pyrrolidone Gamma-butyrolactam 0.1g Raney nickel 0.1g Safrole 5-(2-Propenyl)-1,3-benzodioxide 0.1g Sassafras oil 0.1g Sodium bis(2-methoxyethoxy) aluminium hydride 0.1g Sodium borohydride 0.1g Sodium cyanoborohydride 0.1g Thionyl chloride 0.1g Thorium 0.1g Trans-beta-methylstyrene 0.1g Part 2 Substances that do not include their salts, derivatives and stereo-isomers 2 In this part, a reference to a substance does not include a reference to— (a) a salt, derivative or stereo-isomer of the substance; and (b) a salt of a derivative or stereo-isomer of the substance. Substance Alternative name Gross weight Acetic anhydride 0.1g Calcium metal 0.1g Hydriodic acid Hydrogen iodide solution 0.1g Hydrobromic acid Hydrogen bromide solution 0.1g Iodine 0.1g Lithium metal 25g Magnesium metal 0.1g Mercury metal 0.1g Phosphorous acid Phosphonic Acid 0.1g Phosphorus (red or white) 0.1g Platinum metal 0.1g Potassium metal 0.1g Sodium metal 0.1g Schedule 8B Things specified for ss 9A, 9B, 9C and 9D, and prescribed for s 134, of Act 1 hydrogen sulfide gas cylinder 2 hydrogen chloride gas cylinder 3 hydrogen gas cylinder 4 ammonia gas cylinder 5 condenser 6 distillation head 7 heating mantle 8 manual or mechanical pill press, including a pill press under repair, a modification of a pill press and parts for a pill press 9 reaction vessel, including a reaction vessel under repair or a modification of a reaction vessel 10 rotary evaporator 11 splash head, including a splash head under repair or parts for a splash head Schedule 8C Prohibited combinations of items 1 A combination consisting of substances that are or contain— (a) pseudoephedrine or its salts; and (b) hypophosphorous acid; and (c) iodine. 2 A combination consisting of substances that are or contain— (a) pseudoephedrine or its salts; and (b) hydriodic acid; and (c) phosphorous (red or white). 3 A combination consisting of substances that are or contain— (a) pseudoephedrine or its salts; and (b) lithium metal; and (c) ammonia gas. Schedule 8D Relevant dangerous drugs amphetamine methylamphetamine Schedule 8E Fees Fee units 1 Application fee for a researcher licence (Act, s 54(2)(a)) 1,942.95 2 Application fee for a grower licence (Act, s 54(2)(a)) 1,304.95 3 Application fee for a seed handler licence (Act, s 54(2)(a)) 435.65 4 Licence renewal fee for a researcher licence (Act, s 65(2)(d)(i)) 1,572.85 5 Licence renewal fee for a grower licence (Act, s 65(2)(d)(i)) 1,059.95 6 Licence renewal fee for a seed handler licence (Act, s 65(2)(d)(i)) 435.65 7 Application fee for amendment of a licence or a condition of a licence (Act, s 70(2)) 294.95 8 Monitoring of an activity performed under a relevant authority, for each hour involved (Act, s 110G(1)) 322.05 Notes— 1 See section 28A(2) in relation to a fee for part of an hour. 2 See section 28A(3) and (4) in relation to the fee for an inspector's travel and the cost of analysis of a sample of cannabis for monitoring an activity. Schedule 9 Dictionary analyst means a person who is authorised under the Medicines and Poisons Act 2019 to use standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration. approved research plan, for a researcher licence, means a research plan that forms part of the licence under section 63(4) of the Act as amended in accordance with the Act. carrier means a person who carries on a business of transporting a thing for delivery to the person to whom it is consigned, whether in Queensland or elsewhere, and whether the thing is transported by air, rail, road or sea. condenser means a cooling device for converting gases or vapours to liquid or solid form. consigned includes addressed. consigned cannabis means any of the following— (a) industrial cannabis plants; (b) industrial cannabis seed; (c) class A research cannabis; (d) class B research cannabis; (e) processed cannabis. distillation head means an apparatus that— (a) fits on top of a reaction vessel or a vessel that serves the same purpose as a reaction vessel; and (b) connects to a condenser; and (c) is suitably angled to allow vapour to flow downwards into a collection vessel. DPI researcher means a public service officer— (a) who is employed in the department within which the Biosecurity Act 2014 is administered; and (b) whose duties include plant breeding; and (c) who is authorised by the chief executive in writing to perform activities stated in part 4, division 4. gas cylinder means a cylinder or other thing that— (a) is used for storing gas in any form; and (b) has a storage capacity of less than 1 tonne. heating mantle means a device designed or adapted to heat a reaction vessel or a vessel that serves the same purpose as a reaction vessel. NATA means the National Association of Testing Authorities, Australia ABN 59 004 379 748. NATA accredited laboratory means a laboratory whose functions and operations are accredited by NATA for competence to undertake drug analysis. recipient licensee, in relation to cannabis seed originating in another State or another country, means the licensee who first takes possession of the seed after it enters the State. required particulars means— (a) a report number, or other identifying information, for the report containing the results mentioned in section 11(2)(a)(ii), (3)(a)(ii) or (4)(a)(ii); and (b) the words 'planting seed'; and (c) the words 'This seed was harvested from a cannabis plant with a THC concentration in the plant's leaves and flowering heads, of not more than 0.5%'; and (d) for cannabis seed originating in the State—the name and licence number of the grower who produced the seed; and (e) for cannabis seed originating in another State or another country—the name of— (i) the State or other country; and (ii) the recipient licensee. splash head means an apparatus that fits between a reaction vessel, or a vessel that serves the same purpose as a reaction vessel, and a condenser and stops a heated substance contaminating the distillate. standard THC material means THC of a known purity. supply— (a) for part 3, see section 43A of the Act; or (b) for part 4, does not include administer.